featured
HERITAGE: Equivalence of Trastuzumab-dkst to Trastuzumab in HER2+ Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Final Overall Survival Analysis of the Phase 3 HERITAGE Study Demonstrates Equivalence of Trastuzumab-dkst to Trastuzumab in HER2-Positive Metastatic Breast Cancer
Breast Cancer Res Treat 2021 Jun 14;[EPub Ahead of Print], HS Rugo, EJ Pennella, U Gopalakrishnan, M Hernandez-Bronchud, J Herson, HF Koch, S Loganathan, S Deodhar, A Marwah, A Manikhas, I Bondarenko, G Mukhametshina, G Nemsadze, JD Parra, MLT Abesamis-Tiambeng, K Baramidze, C Akewanlop, I Vynnychenko, V Sriuranpong, G Mamillapalli, S Roy, EP Yanez Ruiz, A Barve, A Fuentes-Alburo, CF WallerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.